AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32660869 — intervention group
Group type: EXPERIMENTAL
Intervention: Trofinetide 70 mg/kg twice daily
Number of subjects: 72
Study 32660869 — intervention group
Group type: EXPERIMENTAL
Intervention: Trofinetide 35 mg/kg twice daily
Number of subjects: 72
Study 32660869 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 34326006 — intervention group
Group type: EXPERIMENTAL
Intervention: PIEZO-ICSI
Number of subjects: 69
Study 34326006 — intervention group
Group type: COMPARATOR
Intervention: Standard ICSI
Number of subjects: 69
Study 36323462 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBOT)
Number of subjects: 80
Study 36323462 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 80
Study 32480252 — intervention group
Group type: EXPERIMENTAL
Intervention: lidocaine/craving
Number of subjects: 33
Study 32480252 — intervention group
Group type: COMPARATOR
Intervention: saline/craving
Number of subjects: 33
Study 32480252 — intervention group
Group type: EXPERIMENTAL
Intervention: lidocaine/relax
Number of subjects: 33
Study 35579159 — intervention group
Group type: EXPERIMENTAL
Intervention: NanoBEO (essential oil of bergamot delivered via a nanotechnology-based system)
Number of subjects: 0
Study 35579159 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 34464503 — intervention group
Group type: EXPERIMENTAL
Intervention: Kidney transplant recipients with cancer
Number of subjects: 1425
Study 34464503 — intervention group
Group type: COMPARATOR
Intervention: Matched controls (cancer-free)
Number of subjects: 1425
Study 34464503 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Hodgkin lymphoma
Number of subjects: 1425
Study 34464503 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung cancer
Number of subjects: 1425
Study 34464503 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast cancer
Number of subjects: 1425
Study 34464503 — intervention group
Group type: EXPERIMENTAL
Intervention: Colon-rectum cancer
Number of subjects: 1425
Study 34464503 — intervention group
Group type: EXPERIMENTAL
Intervention: Kidney cancer
Number of subjects: 1425
Study 34923163 — intervention group
Group type: EXPERIMENTAL
Intervention: Camrelizumab plus chemotherapy (carboplatin and paclitaxel)
Number of subjects: 389
Study 34923163 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus chemotherapy (carboplatin and paclitaxel)
Number of subjects: 389
Study 34923163 — intervention group
Group type: EXPERIMENTAL
Intervention: Camrelizumab plus chemotherapy
Number of subjects: 389
Study 33298197 — intervention group
Group type: EXPERIMENTAL
Intervention: Child dietary diversity
Number of subjects: 512
Study 33298197 — intervention group
Group type: COMPARATOR
Intervention: Food insecurity
Number of subjects: 512
Study 33298197 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers' age and education
Number of subjects: 512
Study 33298197 — intervention group
Group type: EXPERIMENTAL
Intervention: Place of residence and sex of household head
Number of subjects: 512
Study 35568194 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP <200 pg/mL (low)
Number of subjects: 984
Study 35568194 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP 200 to <400 pg/mL (moderate)
Number of subjects: 984
Study 35568194 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP ≥400 pg/mL (high)
Number of subjects: 984
Study 35568194 — intervention group
Group type: COMPARATOR
Intervention: Edoxaban 15 mg
Number of subjects: 984
Study 35568194 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 984
Study 34684135 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-Specific Training after Cognitive Sensorimotor Exercise (TST after CSE), n = 13
Number of subjects: 37
Study 34684135 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-Specific Training (TST), n = 12
Number of subjects: 37
Study 34684135 — intervention group
Group type: COMPARATOR
Intervention: Conventional physical therapy training (control group), n = 12
Number of subjects: 37
Study 32596882 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy for insomnia (CBT-I)
Number of subjects: 46
Study 32596882 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 46
Study 34766586 — intervention group
Group type: EXPERIMENTAL
Intervention: HRVBF (Heart Rate Variability Biofeedback)
Number of subjects: 45
Study 34766586 — intervention group
Group type: COMPARATOR
Intervention: Control group (simple breathing at rest)
Number of subjects: 45
Study 34735740 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychodynamic treatment for BPD
Number of subjects: 39
Study 33289280 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow oxygen
Number of subjects: 74
Study 33289280 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-flow oxygen
Number of subjects: 74
Study 33289280 — intervention group
Group type: COMPARATOR
Intervention: High-flow air
Number of subjects: 74
Study 33289280 — intervention group
Group type: COMPARATOR
Intervention: Low-flow air
Number of subjects: 74
Study 37855897 — intervention group
Group type: EXPERIMENTAL
Intervention: SP TFL with 200 μm fiber
Number of subjects: 96
Study 37855897 — intervention group
Group type: EXPERIMENTAL
Intervention: SP TFL with 150 μm fiber
Number of subjects: 96
Study 37855897 — intervention group
Group type: COMPARATOR
Intervention: Ho:YAG with 200 μm fiber
Number of subjects: 96
Study 32808553 — intervention group
Group type: EXPERIMENTAL
Intervention: Workplace Support for Health (WSH) scale
Number of subjects: 2820
Study 35860900 — intervention group
Group type: EXPERIMENTAL
Intervention: Core stability exercise program (8-week duration)
Number of subjects: 24
Study 35860900 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 24
Study 33528679 — intervention group
Group type: EXPERIMENTAL
Intervention: Three sessions per week
Number of subjects: 45
Study 33528679 — intervention group
Group type: EXPERIMENTAL
Intervention: Two sessions per week
Number of subjects: 45
Study 33528679 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study 32331879 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunixin meglumine (2.2 mg/kg of BW)
Number of subjects: 68
Study 32331879 — intervention group
Group type: COMPARATOR
Intervention: Isotonic sterile saline solution
Number of subjects: 68
Study 33492346 — intervention group
Group type: EXPERIMENTAL
Intervention: Family media use plan
Number of subjects: 1520
Study 33492346 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1520
Study 34856702 — intervention group
Group type: EXPERIMENTAL
Intervention: Early palliative care (EPC) group
Number of subjects: 60
Study 32658399 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% sodium bicarbonate
Number of subjects: 91
Study 32658399 — intervention group
Group type: COMPARATOR
Intervention: Docusate sodium
Number of subjects: 91
Study 35933328 — intervention group
Group type: EXPERIMENTAL
Intervention: PENG block
Number of subjects: 60
Study 35933328 — intervention group
Group type: COMPARATOR
Intervention: Sham block
Number of subjects: 60
Study 36064729 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip strap
Number of subjects: 29
Study 36064729 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot orthoses
Number of subjects: 29
Study 36064729 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 29
Study 32770664 — intervention group
Group type: EXPERIMENTAL
Intervention: Gifting of chickens by a community champion combined with a behaviour change package of integrated poultry management and human nutrition trainings
Number of subjects: 0
Study 32770664 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 36114096 — intervention group
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel (100 mg/m² on days 1, 8, and 15 of a 21-day cycle)
Number of subjects: 503
Study 36114096 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel (60 mg/m² on day 1)
Number of subjects: 503
Study 36114096 — intervention group
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Number of subjects: 503
Study 36114096 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel
Number of subjects: 503
Study 32186967 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-hypnosis treatment program
Number of subjects: 90
Study 34740708 — intervention group
Group type: EXPERIMENTAL
Intervention: Blonanserin transdermal patches (40-80 mg/day)
Number of subjects: 155
Study 34740708 — intervention group
Group type: COMPARATOR
Intervention: Blonanserin transdermal patches
Number of subjects: 155
Study 33007780 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate nasal spray (FFNS) 55 µg
Number of subjects: 0
Study 33007780 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate nasal spray (FFNS) 110 µg
Number of subjects: 0
Study 33007780 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32458495 — intervention group
Group type: EXPERIMENTAL
Intervention: Locomotion replacement training (LRT)
Number of subjects: 10
Study 32458495 — intervention group
Group type: EXPERIMENTAL
Intervention: Standing (STA)
Number of subjects: 10
Study 32458495 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 10
Study 33752752 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-day regimen of post-operative antibiotics
Number of subjects: 600
Study 33752752 — intervention group
Group type: COMPARATOR
Intervention: 1-day regimen of post-operative antibiotics
Number of subjects: 600
Study 35963664 — intervention group
Group type: EXPERIMENTAL
Intervention: CALF
Number of subjects: 40
Study 35963664 — intervention group
Group type: EXPERIMENTAL
Intervention: PRI
Number of subjects: 40
Study 35963664 — intervention group
Group type: EXPERIMENTAL
Intervention: DFI
Number of subjects: 40
Study 35963664 — intervention group
Group type: EXPERIMENTAL
Intervention: MPRI
Number of subjects: 40
Study 32840287 — intervention group
Group type: EXPERIMENTAL
Intervention: RBD-IgM
Number of subjects: 191
Study 32840287 — intervention group
Group type: EXPERIMENTAL
Intervention: S-IgM
Number of subjects: 191
Study 32840287 — intervention group
Group type: EXPERIMENTAL
Intervention: N-IgG
Number of subjects: 191
Study 32840287 — intervention group
Group type: EXPERIMENTAL
Intervention: RBD-IgG
Number of subjects: 191
Study 32840287 — intervention group
Group type: EXPERIMENTAL
Intervention: N-IgM
Number of subjects: 191
Study 32840287 — intervention group
Group type: EXPERIMENTAL
Intervention: NAbs
Number of subjects: 191
Study 32840287 — intervention group
Group type: EXPERIMENTAL
Intervention: S-IgG
Number of subjects: 191
Study 35918630 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training (50 min, 3x/week, intensity between 70 and 85% of maximum HR predicted for age)
Number of subjects: 18
Study 35918630 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 18
Study 35918630 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training (TG)
Number of subjects: 18
Study 33360753 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound guided percutaneous insertion
Number of subjects: 108
Study 33360753 — intervention group
Group type: COMPARATOR
Intervention: Open insertion
Number of subjects: 108
Study 616539009 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive peer coaching and nurse case management
Number of subjects: 0
Study 616539009 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive peer coaching
Number of subjects: 0
Study 616539009 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief nurse counseling
Number of subjects: 0
Study 616539009 — intervention group
Group type: COMPARATOR
Intervention: Usual care control treatment (including brief peer coaching and brief nurse counseling)
Number of subjects: 0
Study 616539009 — intervention group
Group type: EXPERIMENTAL
Intervention: All interventions (including control)
Number of subjects: 0
Study 36197309 — intervention group
Group type: EXPERIMENTAL
Intervention: AVT02 administered via prefilled syringe (PFS)
Number of subjects: 207
Study 36197309 — intervention group
Group type: EXPERIMENTAL
Intervention: AVT02 administered via autoinjector (AI)
Number of subjects: 207
Study 36197309 — intervention group
Group type: COMPARATOR
Intervention: AVT02 administered via PFS
Number of subjects: 207
Study 36197309 — intervention group
Group type: COMPARATOR
Intervention: AVT02 administered via AI
Number of subjects: 207
Study 32915370 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 64
Study 32915370 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 64
Study 32493411 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall adjustment acupuncture (OA)
Number of subjects: 104
Study 32493411 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture (SA)
Number of subjects: 104
Study 36062569 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (4 g daily)
Number of subjects: 60
Study 36062569 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (1.5 g daily)
Number of subjects: 60
Study 36062569 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of probiotics and metformin
Number of subjects: 60
Study 34639792 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored cigarette warning messages (gain versus loss framing; short-term versus long-term framing)
Number of subjects: 512
Study 34639792 — intervention group
Group type: EXPERIMENTAL
Intervention: Messages congruent with individual loss aversion and delay discounting rates
Number of subjects: 512
Study 34639792 — intervention group
Group type: COMPARATOR
Intervention: Control group (no tailored messages)
Number of subjects: 512
Study 32473149 — intervention group
Group type: EXPERIMENTAL
Intervention: Height for age z scores in the first 2 years of life
Number of subjects: 791
Study 32473149 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in height for age z scores between early and later childhood
Number of subjects: 791
Study 34499273 — intervention group
Group type: EXPERIMENTAL
Intervention: APERS-based intervention
Number of subjects: 0
Study 34499273 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 34146697 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 7
Study 35877037 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 33705475 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label placebo (OLP) plus treatment as usual (TAU)
Number of subjects: 54
Study 33705475 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 54
Study 33705475 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label placebo (OLP)
Number of subjects: 54
Study 34073401 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin (single dose according to body weight)
Number of subjects: 100
Study 34073401 — intervention group
Group type: COMPARATOR
Intervention: Standard preventive treatment (mainly supplements)
Number of subjects: 100
Study 34073401 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin
Number of subjects: 100
Study 34073401 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study 32312114 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonothrombolysis and percutaneous coronary intervention
Number of subjects: 100
Study 32312114 — intervention group
Group type: COMPARATOR
Intervention: Control (percutaneous coronary intervention only)
Number of subjects: 100
Study 36295487 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet‐rich fibrin (PRF)
Number of subjects: 26
Study 36295487 — intervention group
Group type: COMPARATOR
Intervention: Connective tissue graft (CTG)
Number of subjects: 26
Study 33754455 — intervention group
Group type: EXPERIMENTAL
Intervention: Single daily dosing (0.3 mg/kg/dose)
Number of subjects: 194
Study 33754455 — intervention group
Group type: COMPARATOR
Intervention: Divided dosing (0.15 mg/kg/dose every 8 hours)
Number of subjects: 194
Study 33754455 — intervention group
Group type: EXPERIMENTAL
Intervention: Both dosing strategies
Number of subjects: 194
Study 32195801 — intervention group
Group type: EXPERIMENTAL
Intervention: p‐COP‐determined iodine dose (Group A, n = 65)
Number of subjects: 130
Study 32195801 — intervention group
Group type: COMPARATOR
Intervention: Standard protocol (Group B, n = 65)
Number of subjects: 130
Study 35946167 — intervention group
Group type: EXPERIMENTAL
Intervention: DIALOG+ intervention
Number of subjects: 468
Study 33706070 — intervention group
Group type: EXPERIMENTAL
Intervention: Menthol cigarette users
Number of subjects: 268
Study 33706070 — intervention group
Group type: COMPARATOR
Intervention: Non-menthol cigarette users
Number of subjects: 268
Study 35103587 — intervention group
Group type: EXPERIMENTAL
Intervention: FDC hard capsule containing CC/HCTZ/RSV
Number of subjects: 24
Study 33622507 — intervention group
Group type: EXPERIMENTAL
Intervention: TCIT-U
Number of subjects: 144
Study 33622507 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 144
Study 36109821 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-h online resourcefulness training
Number of subjects: 60
Study 36109821 — intervention group
Group type: COMPARATOR
Intervention: Conventional training (psychological training, psychological counseling)
Number of subjects: 60
Study 32985902 — intervention group
Group type: EXPERIMENTAL
Intervention: Zanubrutinib plus rituximab followed by zanubrutinib monotherapy
Number of subjects: 0
Study 32985902 — intervention group
Group type: COMPARATOR
Intervention: Bendamustine plus rituximab followed by observation
Number of subjects: 0
Study 35367015 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovarian fragmentation for follicular activation (OFFA)
Number of subjects: 34
Study 35367015 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 34
Study 34016263 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide (glucagon-like peptide-1 analog) for 1 year
Number of subjects: 633
Study 34016263 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (not specified)
Number of subjects: 633
Study 34016263 — intervention group
Group type: EXPERIMENTAL
Intervention: C16:0‐ceramide
Number of subjects: 633
Study 34016263 — intervention group
Group type: EXPERIMENTAL
Intervention: C16:0‐glycosylceramide
Number of subjects: 633
Study 32531622 — intervention group
Group type: EXPERIMENTAL
Intervention: Gelfoam
Number of subjects: 78
Study 32531622 — intervention group
Group type: EXPERIMENTAL
Intervention: Silastic sheets
Number of subjects: 78
Study 35181293 — intervention group
Group type: EXPERIMENTAL
Intervention: High energy preload
Number of subjects: 66
Study 35181293 — intervention group
Group type: EXPERIMENTAL
Intervention: Low energy preload
Number of subjects: 66
Study 33440999 — intervention group
Group type: EXPERIMENTAL
Intervention: Short SBT (≤2 hours)
Number of subjects: 3115
Study 33440999 — intervention group
Group type: EXPERIMENTAL
Intervention: Long SBT (>4 hours)
Number of subjects: 3115
Study 33440999 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate SBT (2-4 hours)
Number of subjects: 3115
Study 33440999 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate DBT (45-90 minutes)
Number of subjects: 3115
Study 33440999 — intervention group
Group type: EXPERIMENTAL
Intervention: Long DBT (>90 minutes)
Number of subjects: 3115
Study 34905069 — intervention group
Group type: EXPERIMENTAL
Intervention: PROT + TIMING
Number of subjects: 0
Study 32783367 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist pretreatment (n=172)
Number of subjects: 343
Study 32783367 — intervention group
Group type: COMPARATOR
Intervention: Control group (no GnRH agonist pretreatment, n=171)
Number of subjects: 343
Study 32345077 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 µg alfacalcidol daily for 12 weeks
Number of subjects: 77
Study 32345077 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 77
Study 32154928 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab 10 mg/kg every 2 weeks plus trebananib 15 mg/kg every week
Number of subjects: 115
Study 32154928 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab plus placebo
Number of subjects: 115
Study 35038985 — intervention group
Group type: EXPERIMENTAL
Intervention: In-Home Cognitive Processing Therapy (CPT)
Number of subjects: 120
Study 35038985 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth Cognitive Processing Therapy (CPT)
Number of subjects: 120
Study 35038985 — intervention group
Group type: EXPERIMENTAL
Intervention: In-Office Cognitive Processing Therapy (CPT)
Number of subjects: 120
Study 35038985 — intervention group
Group type: COMPARATOR
Intervention: In-Home vs Telehealth
Number of subjects: 120
Study 35038985 — intervention group
Group type: COMPARATOR
Intervention: In-Home vs Telehealth vs In-Office (Dropout rates)
Number of subjects: 120
Study 33327240 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Maxing Shigan Decoction
Number of subjects: 240
Study 33327240 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Qingfei Decoction
Number of subjects: 240
Study 33327240 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study 35636686 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg/kg
Number of subjects: 124
Study 35636686 — intervention group
Group type: COMPARATOR
Intervention: Succinylcholine 1.5 mg/kg
Number of subjects: 124
Study 33766084 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin supplementation (250 mg, two tablets once a day for 8 weeks)
Number of subjects: 50
Study 32171997 — intervention group
Group type: EXPERIMENTAL
Intervention: Attentional Bias Modification (ABM)
Number of subjects: 79
Study 32171997 — intervention group
Group type: COMPARATOR
Intervention: Control training
Number of subjects: 79
Study 36131214 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Number of subjects: 0
Study 33151634 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive and behavioral therapy (CBT) plus antidepressants
Number of subjects: 28
Study 35051281 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-year multi-domain intervention with diet, physical and cognitive activity, and vascular monitoring (n=631)
Number of subjects: 1259
Study 35051281 — intervention group
Group type: COMPARATOR
Intervention: General health advice (n=628)
Number of subjects: 1259
Study 35051281 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-year multi-domain intervention among those with history of CVD (n=145)
Number of subjects: 1259